Gemtuzumab ozogamicin in acute myeloid leukemia revisited (Q38215269)

31 August 2017

title

Gemtuzumab ozogamicin in acute myeloid leukemia revisited (English)

1 reference

31 August 2017

1 reference

acute myeloid leukemia

1 reference

Felicitas Thol

1

1 reference

31 August 2017

Richard F Schlenk

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

28 May 2014

1 reference

Expert Opinion on Biological Therapy

31 August 2017

published in

1 reference

31 August 2017

volume

14

1 reference

31 August 2017

issue

8

1 reference

31 August 2017

page(s)

1185-1195

1 reference

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Antibody therapy for acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Siglecs and their roles in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2014.922534

10.1517/14712598.2014.922534

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference